Physician profile
Hannah Johnson
NPI 1588194708
$5,244.35
in general payments reported to CMS, 2019-2025
23 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,051 · 2022: $1,211 · 2023: $947 · 2024: $1,007 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,442.31 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $829.29 | 2021-2025 | |
| Lilly USA, LLC | $594.81 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $384.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $323.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $317.23 | 2022-2025 | Repatha, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.20 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.50 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $145.19 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.38 | 2022-2024 | Caplyta |
| Novo Nordisk INC | $127.13 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $105.93 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $91.46 | 2021 | |
| Abbott Laboratories | $91.05 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $84.39 | 2021-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $33.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.01 | 2024 | Ajovy |
| Janssen Pharmaceuticals, INC | $25.26 | 2023 | Xarelto |
| Inspire Medical Systems, INC. | $20.65 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $20.41 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $19.62 | 2022 | |
| Medtronic, INC. | $18.56 | 2022 | |
| Becton, Dickinson and Company | $17.55 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.